A child aged 2 years 8 months was referred to our rheumatology unit for evaluation of recurrent acute pain and limited motion of the left hip. In March 2003 he had been seen at the emergency department of our hospital for a painful, flexed, and abducted left hip. On that occasion, the erythrocyte sedimentation rate (ESR) was 35 mm/1st h, white blood cells (WBC) \(8.3 \times 10^9/l\), and C reactive protein (CRP) 32.7 mg/l (normal value <5 mg/l). Ultrasound of the joint showed mild effusion with normal synovial thickness on the left hip, and a transient hip synovitis (THS) was diagnosed. The pain and limp responded to a 3 day course of anti-inflammatory drug treatment.

One month later, the boy returned again with a limp and pain in the left hip. Because the symptoms resolved over few days with analgesic administration, laboratory tests or ultrasound were not performed.

The child was well up to November 2003, when the hip pain and limping returned without any other musculoskeletal or constitutional symptoms. Abnormal laboratory results were as follows: ESR 34 mm/1st h, CRP 6.5 mg/l, WBC \(5.9 \times 10^9/l\) (neutrophils 45.3%, lymphocytes 44.3%), haemoglobin 109 g/l, platelet count \(127 \times 10^9/l\), serum lactate dehydrogenase (LDH) 1216 U/l (normal value <560). Bacterial and viral infections were all excluded. Ultrasound of both hips excluded joint effusion, while an x ray examination showed an area of reduced bone density in the left femoral neck. Magnetic resonance imaging with gadolinium showed focci of increased uptake in bone marrow of the left ileum and in periarticular left ischiopubic and ileopubic areas close to the hip. Although a peripheral blood smear did not disclose any abnormality, a bone marrow aspirate analysis showed a myeloblastic leukaemia FAB M2 (fig 1). The boy was then referred to the oncology unit.

**DISCUSSION**

Limping is a common and challenging problem in children and adolescents. A complete history and thorough physical examination with pertinent laboratory tests and imaging studies are necessary to establish an early diagnosis.1

In the absence of constitutional symptoms, THS is the most common cause of sudden onset of limp and flexed and abducted hip in a young boy. The measures of inflammation are normal or slightly raised, joint ultrasound shows effusion on the hip, and x ray findings may be normal or show widening of the joint space. The condition may recur and responds to a short treatment with analgesic.2

In our patient, the clinical symptoms suggested a diagnosis of THS at initial presentation. After the third episode of limping, an x ray examination was recommended to rule out osteonecrosis of the femoral head, a possible complication of THS in about 3% of patients. The increased level of LDH prompted us to investigate further by means of a bone marrow aspirate. In children with musculoskeletal complaints, increased values of LDH may help to distinguish patients with rheumatic diseases from those with malignancies at the beginning of illness when symptoms and other laboratory data are not yet helpful.3 4

**REFERENCES**

Finger joint swellings in a teenager: juvenile rheumatoid arthritis or a psychiatric disorder?

B Ostendorf, C Iking-Konert, M Cohnen, M Schneider


In January 2002 a 14 year old Turkish teenager presented to his doctor with a history of 3 months' swelling of the proximal interphalangeal (PIP) joints of both hands. As arthritis was suspected, he was referred to an orthopaedic surgeon. Blood tests, including C reactive protein, rheumatoid factor, were normal, conventional radiography of both hands showed only soft tissue swellings of the PIP joints. Under the diagnosis of “juvenile rheumatoid arthritis”, treatment with a non-steroidal anti-inflammatory drug was started. As the “polyarthritis” persisted, he was introduced to another orthopaedist. Three phase bone scintigraphy (technetium-99m) disclosed intensive “hot spots” at the PIP joints (phase 2) and at the epiphysial growth plate of the upper and lower extremities (static bone phase).

In July 2003, after three other medical consultations, he was admitted to our department. He denied any other symptoms or complaints besides finger swellings (fig 1), predominantly of PIP 2 and 3 of both hands, without signs of hypermobility and functional restriction. Routine blood tests, erythrocyte sedimentation rate, C reactive protein, rheumatoid factor, cyclic citrullinated peptide, antinuclear antibodies, and HLA-B27 were normal. Follow up radiographs of hands and feet (posteroanterior and oblique) were normal (Larsen score 1) and showed non-consolidated epiphyses. Tendon or ligament injuries, signs of synovial effusion, or active synovitis were not detected by ultrasound (12.5 MHz high frequency transducer). To detect early signs of arthritis, magnetic resonance imaging (MRI; 1.5 T) of the right hand was performed, showing periarticular swelling of the joint capsules of the PIP joints (fig 2); no osseous oedema, erosions, cystic lesions, or synovitis after intravenous gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA; Magnevist, Schering AG, Berlin; not shown) was seen.

We discussed the discrepancy between the clinical findings and diagnostic results, and he finally reported a nervous habit that he had had for at least 2 years: cracking his fingers 10 times a minute. This psychiatric disorder had remained undetected during various medical consultations. In view of these new aspects, the MRI sections were re-evaluated, but tendon, ligament, or finger pulley injuries could be ruled out. The patient was discharged with the diagnosis of an “overuse syndrome secondary to a nervous tick” and was referred to a psychiatric consultant for behaviour therapy, which he stopped after a few sessions without having benefited.

DISCUSSION

In our patient only severe swellings of the PIP joints of both hands correspond to the revised criteria of juvenile idiopathic arthritis (JIA).1 Because of the discrepancies in the former diagnostic findings, we performed MRI, which disclosed periarticular swellings of the PIP joints but neither synovitis nor damage to cartilage or bone. Based on this, we re-evaluated the patient’s history radically. Finally, the young man admitted cracking his fingers continuously for the past 2 years, a fact that led to the diagnosis of an “overuse syndrome secondary to a nervous tick”2 as a psychiatric disorder and not to JIA. Neither specific hints in his history for a factitious disease/Munchhausen syndrome3 nor criteria for joint hypermobility syndromes,4 heritable disorders of connective tissue or storage diseases, Thiemann’s disease5 or osteochondrodysplasia could be found. The patient’s...
swellings were most probably due to chronic overuse and extensive stress of the PIP joints, a phenomenon known to some extent in, for example, extreme rock climbers.²

Ultrasound and MRI have emerged as alternatives or supplements to conventional radiography in imaging small joint abnormalities in patients with arthritis or trauma.²⁻⁷ MRI visualises structural bone damage (oedema and erosions) as well as signs of disease activity (synovitis) as indicated by Gd-DTPA. However, MRI is not usually necessary to reach a diagnosis of JIA, but when there are atypical features and diagnostic doubt, it is a useful additional investigative tool. In our case, MRI helped to exclude both JIA and minor traumatic lesions, once we had become aware of the patient’s overuse syndrome.

**Authors’ affiliations**

B Ostendorf, C Iking-Konert, M Schneider, Department of Rheumatology, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany

M Cohnen, Institute of Diagnostic Radiology, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany

Editor: Anthony D Woolf

Correspondence to: Dr B Ostendorf, ostendorf@med.uni-duesseldorf.de

Accepted 5 August 2004

---

**Worse patient VAS occurs at weeks 7 and 8 after infliximab infusions**

N Shenker, R Haigh, A Clarke

The new tumour necrosis factor α (TNFα) blockers are revolutionising the treatment of patients with resistant rheumatoid arthritis. Generally good response rates are seen and the treatments are well tolerated. These agents, however, are costly and questions about their long term side effects remain. In the UK, the administration of infliximab and etanercept has been reviewed by NICE, and guidelines were published in March, 2002¹. They recommend that “non-responders” discontinue treatment after 3 months. Non-responders are defined by a Disease Activity Score using a 28 joint count (DAS28) that remains greater than 3.2 or has not reduced by at least 1.2 from the score before treatment.

Anecdotal evidence suggests that patients become increasingly symptomatic towards the end of the 8 weeks between infusions. Therefore, despite an obvious sustained clinical improvement immediately after their infusion, their DAS28 may still be high at the eighth week. We have previously described a patient with active rheumatoid arthritis whose disease did not respond to the 8 weekly regimen but who has continued to have good disease control with a 6 weekly regimen.² Does patient wellbeing deteriorate over the 8 weeks for patients already established on infliximab? We asked all our patients on such a regimen to rate their disease on a self administered patient global wellbeing visual analogue scale (VAS) for each of the 8 weeks between infusions. Eighteen patients were identified and all successfully completed the VAS sheets. The Wilcoxon signed rank test using week 1 as comparator was used to detect significance. Figure 1 presents the results obtained.

**REFERENCES**


---

**TABLE 1**

<table>
<thead>
<tr>
<th>Time (weeks)</th>
<th>VAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
</tr>
<tr>
<td>3</td>
<td>46</td>
</tr>
<tr>
<td>4</td>
<td>44</td>
</tr>
<tr>
<td>5</td>
<td>42</td>
</tr>
<tr>
<td>6</td>
<td>40</td>
</tr>
<tr>
<td>7</td>
<td>38</td>
</tr>
<tr>
<td>8</td>
<td>36</td>
</tr>
</tbody>
</table>

This survey uses a simple but pragmatic outcome measure (patient global wellbeing VAS) to indicate that patients who receive infliximab do not have a uniform sustained response. There was a significant trend for patients to notice a general improvement immediately after their infusion, their DAS28 effects remain. In the UK, the administration of infliximab and etanercept has been reviewed by NICE, and guidelines were published in March, 2002¹. They recommend that “non-responders” discontinue treatment after 3 months. Non-responders are defined by a Disease Activity Score using a 28 joint count (DAS28) that remains greater than 3.2 or has not reduced by at least 1.2 from the score before treatment.

Anecdotal evidence suggests that patients become increasingly symptomatic towards the end of the 8 weeks between infusions. Therefore, despite an obvious sustained clinical improvement immediately after their infusion, their DAS28 may still be high at the eighth week. We have previously described a patient with active rheumatoid arthritis whose disease did not respond to the 8 weekly regimen but who has continued to have good disease control with a 6 weekly regimen.² Does patient wellbeing deteriorate over the 8 weeks for patients already established on infliximab? We asked all our patients on such a regimen to rate their disease on a self administered patient global wellbeing visual analogue scale (VAS) for each of the 8 weeks between infusions. Eighteen patients were identified and all successfully completed the VAS sheets. The Wilcoxon signed rank test using week 1 as comparator was used to detect significance. Figure 1 presents the results obtained.

**REFERENCES**


---

**TABLE 1**

<table>
<thead>
<tr>
<th>Time (weeks)</th>
<th>VAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
</tr>
<tr>
<td>3</td>
<td>46</td>
</tr>
<tr>
<td>4</td>
<td>44</td>
</tr>
<tr>
<td>5</td>
<td>42</td>
</tr>
<tr>
<td>6</td>
<td>40</td>
</tr>
<tr>
<td>7</td>
<td>38</td>
</tr>
<tr>
<td>8</td>
<td>36</td>
</tr>
</tbody>
</table>

This survey uses a simple but pragmatic outcome measure (patient global wellbeing VAS) to indicate that patients who receive infliximab do not have a uniform sustained response. There was a significant trend for patients to notice a general decrease in their wellbeing towards the end of the 8 week interval. It should be noted that a global patient VAS is a subjective measure that can be influenced by the patient’s expectations. A patient’s global VAS, however, is used as a
component of the more objective DAS28. Clearly, the DAS28 will vary depending upon its temporal relationship with respect to the infusion.

Disease response to infliximab has been related to serum levels.\(^4\) Individual variations in pharmacodynamics mean that in a proportion of patients infliximab clears more rapidly. St Clair et al found that 26% of all patients had undetectable trough levels of serum infliximab at week 54 on a 3 mg/kg 8 weekly regimen.\(^3\) Maini et al noted that patients not treated with methotrexate cleared serum infliximab more rapidly. The role of new antibody production in this observation is unclear at present but may be relevant.\(^2\) Should patients have their trough serum infliximab levels measured before being classified as a “non-responder” in the current national guidelines?

If patients with undetectable trough serum infliximab levels are identified, how should they be treated? Should they have higher doses, such as 5 mg/kg and an 8 weekly regimen, or more frequent infusions? St Clair et al compared 3 mg/kg 6 weekly regimens with a dose increase of 100 mg using pharmacodynamic modelling and concluded that a 6 weekly regimen would yield a higher trough serum level.

In conclusion, TNF\(\alpha\) antagonists are an effective but costly treatment for rheumatoid arthritis. We have performed a pragmatic survey demonstrating a decrease in patient wellbeing over the 8 weeks between infliximab infusions. Non-responders should not be defined by looking at the week 8 DAS28 without taking the clinical response over time into account. This finding has implications for the frequency of infliximab administration and the timing of DAS28 assessments.

**Authors’ affiliations**

N Shenker, A Clarke, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, BA1 1LX, UK

R Haigh, Department of Rheumatology, Royal Devon and Exeter Hospital, Exeter, UK

**Correspondence to:** Dr N Shenker, mpxns@bath.ac.uk

**Accepted 7 April 2004**

**REFERENCES**


---

**Glucocorticoid receptor polymorphisms in Korean patients with rheumatoid arthritis**

**E B Lee, J Y Kim, Y J Lee, Y W Song**

It has been suggested that dysregulation of the neuroendocrine system is an important pathogenetic mechanism of rheumatoid arthritis (RA). The dramatic response of patients with RA to glucocorticoids, the aggravation of RA after resection of bilateral adrenal glands, the inappropriately normal plasma cortisol levels in patients with RA, the blunted plasma cortisol responses after surgical stress, and the essential role of glucocorticoids in the development of streptococcal cell wall induced arthritis in Lewis rats provide evidence that dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis or relative glucocorticoid deficiency might play a part in the development of RA.\(^1\) The involvement of glucocorticoids in the development of thymocytes further supports the role of glucocorticoid in autoimmune diseases like RA.\(^2\)

The human glucocorticoid receptor (hGR) is a transcriptional factor activated by glucocorticoids, and regulates the expressions of various inflammatory cytokine genes by interacting with DNA bound NF-kB or activator protein 1. The hGR gene is located on chromosome 5 (locus 5q31) and consists of nine exons and eight introns.\(^3\) Of the several single nucleotide polymorphisms identified in the hGR gene, the BclI restriction fragment length polymorphism (RFLP) was found to be located in intron 2, 647 bp from the exon 2/intron 2 junction.\(^4\)

BclI RFLP was found to be associated with tissue-specific corticosteroid sensitivity.\(^5\) Furthermore, BclI GG homozygotes showed increased cortisol response to a standardised lunch\(^6\) and depressed response to severe psychosocial stress. These findings suggest that the BclI polymorphism of hGR plays a part in the dysregulation of the HPA axis. The role of the BclI polymorphism in corticosteroid sensitivity and dysregulation of the HPA axis suggests that it may play a part in the pathogenesis of RA. Therefore, we investigated the hGR +647 G/C genetic polymorphism in Korean patients with RA and in healthy blood donors matched for age and sex, in an attempt to understand the role of the HPA axis related hGR polymorphism in the development of RA.

A total of 149 Korean patients with RA were enrolled at the rheumatology clinic of Seoul National University Hospital between March 1998 and February 2000. All patients fulfilled the 1987 American Rheumatism Association revised criteria for the classification of RA.\(^7\) The patients comprised 132 women and 17 men, with mean (SD) age 50.8 (12.1) years and a mean disease duration of 7.9 years (range 0.17–50.2). Rheumatoid factor was present in 112 (75%) and HLA-DR4 in 86 (58%), radiographic erosions were found in 100 (67%), and extra-articular complications in 25 (17%) patients. One hundred and forty nine Korean healthy blood donors matched for age and sex were enrolled as controls.

Genomic DNA was extracted from peripheral blood using a QiAamp blood kit (Qiagen, Valencia, USA), and HLA-DR4 was genotyped by polymerase chain reaction (PCR)-single strand conformation polymorphism. The hGR +647 G/C polymorphism was genotyped by PCR-RFLP, using
**Table 1** Bcll restriction fragment length polymorphism of human glucocorticoid receptor gene in Korean patients with RA versus healthy controls

<table>
<thead>
<tr>
<th>Genotype</th>
<th>RA (n = 149)</th>
<th>Controls (n = 149)</th>
<th>( \chi^2 )</th>
<th>p Value</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>GG</td>
<td>77 (51.7)</td>
<td>86 (57.7)</td>
<td>2.55</td>
<td>0.28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GC</td>
<td>63 (42.3)</td>
<td>59 (39.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>9 (6.0)</td>
<td>4 (2.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Allele**

<table>
<thead>
<tr>
<th>Allele</th>
<th>RA (n = 149)</th>
<th>Controls (n = 149)</th>
<th>( \chi^2 )</th>
<th>p Value</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>G</td>
<td>217 (72.8)</td>
<td>231 (77.5)</td>
<td>1.76</td>
<td>0.18</td>
<td>0.78</td>
<td>0.53 to 1.13</td>
</tr>
<tr>
<td>C</td>
<td>81 (27.2)</td>
<td>67 (22.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACKNOWLEDGEMENTS

This study was supported by a grant from the Ministry of Science and Technology of Korea through the National Research Laboratory Programme.

Authors’ affiliations

E B Lee, J Y Kim, Y J Lee, Y W Song, Department of Internal Medicine, Clinical Research Institute, Medical Research Centre, Seoul National University College of Medicine, Seoul, Korea

Correspondence to: Professor Y W Song, Department of Internal Medicine, Seoul National University College of Medicine, 28 Yungandr, Chongno-gu, Seoul 110–744, Korea; ysong@snu.ac.kr

Accepted 20 June 2004

REFERENCES


Tenascin-X: a candidate gene for benign joint hypermobility syndrome and hypermobility type Ehlers-Danlos syndrome?

M C Zweers, M Kucharekova, J Schalkwijk

Joint hypermobility is a common finding, differing strongly between sexes and among races. Joint hypermobility is not a disease in itself, but it can be part of heritable connective tissue disorders, such as Marfan syndrome, Ehlers-Danlos syndrome (EDS), and benign joint hypermobility syndrome (BJHS). Although Marfan syndrome and most types of EDS are clinically relatively easy to distinguish by their cardinal features, it is often less easy to differentiate between the hypermobility type of EDS (HT-EDS, formerly type III) and BJHS. Recently, Grahame et al proposed a validated set of diagnostic criteria for BJHS: the revised Brighton 1998 criteria. Its major criteria are a Beighton score of 4/9 or greater and arthralgia, but the diagnosis can also be based on the presence of minor criteria, including abnormal skin and joint (sub)luxations. HT-EDS can be identified by the Villefranche criteria; the major criteria of this classification include a Beighton score of 5/9 or greater and skin involvement. Clearly, there is considerable overlap in the clinical features of BJHS and HT-EDS.

Little is known about the genetic basis of HT-EDS or BJHS. Recently, we have shown that haploinsufficiency for the extracellular matrix protein tenascin-X is associated with HT-EDS. Tenascin-X is abundantly expressed in almost all connective tissues, and a 140 kDa fragment is present in

www.annrheumdis.com

Letters


on October 14, 2023 by guest. Protected by copyright.
serum. The level of serum tenascin-X probably reflects the rate of tenascin-X synthesis in the connective tissues, because subjects who are heterozygous for a tenascin-X null allele express about half of the normal level in their serum. Clinically, tenascin-X haploinsufficient subjects show generalised joint hypermobility, arthralgia, and about 40% of them have abnormal skin.

In this study, we investigated whether haploinsufficiency for tenascin-X also occurs in subjects who are diagnosed with BJHS. In collaboration with the Dutch BJHS patient organisation, we collected serum samples from 54 patients (53 female) diagnosed with BJHS by a medical specialist, most of whom were rheumatologists. We measured tenascin-X serum levels in these patients, and found that the mean (SD) level in the BJHS cohort group did not differ from that in the control group (97.6 (25.8)% vs 100 (14.1)%, respectively). Of these patients, 14 (26%) had a tenascin-X serum level below the 5th centile of the controls (crude odds ratio 6.4, 95% confidence interval 2.5 to 16.3). Furthermore, four of these patients (7%, all female) had serum tenascin-X levels more than 2.5 standard deviations of control (65%) below the mean for normal subjects. Only 0.6% of subjects would be expected to have such low tenascin-X serum values based on the normal distribution, which is significantly less than the prevalence found in this BJHS group (p<0.05, Fisher’s exact test). Interestingly, the percentage of reduced tenascin-X serum levels in BJHS is similar to the percentage we described in HT-EDS. None of the previously identified truncating tenascin-X mutations were present in any of the patients. It is likely that these patients may have other mutations of tenascin-X or they may represent the extreme in normal variation of tenascin-X expression. Only two patients were available for clinical examination. Both patients had hypermobile joints, often associated with joint subluxations, and chronic musculoskeletal pain.

We have shown that reduced tenascin-X serum levels are present in 5–10% of the patients diagnosed with BJHS or HT-EDS. These findings and the considerable overlap of the clinical symptoms suggest that no meaningful distinction can be made between these conditions. Both BJHS and HT-EDS are likely to be genetically heterogeneous and, clearly, the search for candidate genes has only just begun.

Authors’ affiliations
M C Zweers, J Schalkwijk, Department of Dermatology, University Medical Centre Nijmegen, The Netherlands
M Kucharekova, Department of Dermatology, University Hospital Maastricht, The Netherlands
Correspondence to: Ms M C Zweers, Department of Dermatology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands; m.zweers@derma.umcn.nl
Accepted 16 July 2004

REFERENCES

Multiple venous thrombosis in SAPHO syndrome
T Kawabata, Y Morita, A Nakatsuka, H Kagawa, M Kawashima, T Sei, M Yamamura, H Makino

A 42 year old Japanese woman presented to our clinic complaining of severe pain in her neck, both shoulders, and lumbar spine. She had had pustulosis palmaris and plantaris from age 16 and recurrent painful swelling of the clavicles, the sternoclavicular joints, and the sternum from age 25. She reported multiple visits to the doctor for similar symptoms, and she was treated with non-steroidal anti-inflammatory drugs.

On initial examination at our clinic, her lumbar and cervical spine mobility was limited considerably. She had an oedematous face and subcutaneous collateral circulation on chest and abdomen. Laboratory testing showed a white cell count of 13.5×10⁹/l and a C reactive protein of 142 mg/l (normal <5). Antinuclear antibodies, antineutrophil cytoplasmic antibodies, anticardiolipin antibodies, lupus anticoagulants, and rheumatoid factors were all negative. Prothrombin time and activated partial thromboplastin time were normal. Locus B HLA typing was positive for B48 and B52. She reported that her C reactive protein level was always over 100 mg/l.

Plain radiographs disclosed marked hyperostosis in the medial aspect of both clavicles. There was narrowing and ankylosis in the apophyseal joints of the cervical spine, and complete ankylosis in both sacroiliac joints. Contrast enhanced computed tomographic scans demonstrated a soft tissue mass in the upper mediastinum (fig 1A). Both subclavian veins were severely stenotic, and the superior vena cava (SVC) was almost completely occluded (fig 1B). Thrombosis was seen within the left internal jugular vein, and the right internal jugular vein could not be observed (fig 1C). Injection of contrast medium showed a network of collateral veins in the neck, chest, and abdominal wall. A diagnosis of SAPHO syndrome complicated by multiple venous thrombosis and SVC syndrome was made. Prednisolone was given at 10 mg/day, and the pain in her shoulders, neck, and lumbar spine improved. The treatment also included warfarin for anticoagulation.

DISCUSSION
Venous thrombosis complicating SAPHO syndrome is uncommon. In a series of 120 patients with this syndrome, Hayem et al found that only one (0.8%) patient had thrombosis of the subclavian vein.¹ We found eight well documented cases of patients with SAPHO syndrome who developed venous thrombosis.² ³ Six of the patients had subclavian vein thrombosis,² ³ and only one case had SVC
obstruction.7 In one of the eight patients, thrombosis of the iliac vein was found in a patient with lumbar vertebral osteitis and a large tissue mass surrounding the vein.8 The pathological mechanisms of venous thrombosis are still not clearly understood, but it is suggested that it is caused by vein compression by hyperostosis, or sheathing of the veins by an inflammatory and fibrotic tissue mass. We have observed a new case of SVC obstruction in SAPHO syndrome, which is of particular interest, as multiple thrombi were observed, not only in the SVC and both subclavian veins but also in the internal jugular vein, which is not directly adjacent to the affected bones and the mediastinal mass. In our case the congestive venous flow may reflect the thrombosis in the internal jugular vein. Van Holsbeeck et al reported a case of a patient with SAPHO syndrome with bilateral subclavian vein obstruction who had a high level of lupus anticoagulant.9 Although our patient does not have any antiphospholipid antibodies, such factors may be associated with venous thrombosis in this syndrome.

SAPHO syndrome has some features of the spondyloarthropathies. Whether this syndrome is a unique subset of the spondyloarthropathies or is a distinct clinical entity is not well established. Nevertheless, the concept of SAPHO syndrome is useful in defining a subgroup of patients with unique clinical features. Venous thrombosis may lead to serious complications in patients with this syndrome. Our patient further emphasises the importance of recognising this complication in SAPHO syndrome.

Authors’ affiliations
T Kawabata, A Nakatuka, H Kagawa, M Kawashima, M Yamamura, H Makino, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Japan

Y Morita, Division of Nephrology and Rheumatology, Department of Internal Medicine, Kawasaki Medical School, Japan

T Sei, Department of Radiology, Okayama University Graduate School of Medicine and Dentistry, Japan

Correspondence to: Dr Y Morita, Division of Nephrology and Rheumatology, Department of Internal Medicine, Kawasaki Medical School, 577 Mutsushita, Kurashiki 710–0192, Japan; morita@med.kawasaki-m.ac.jp

Accepted 10 September 2004

REFERENCES

A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis

P V Gardiner, A L Bell, A J Taggart, G Wright, F Kee, A Smyth, R McKane, J Lee, M E Rooney, E Whitehead

The Disease Activity Score (DAS) is widely used to quantify disease activity and gauge response to treatment. A rather complex calculation conceals the relative contribution of each measure to the composite score. The 28 joint version (DAS28) is used in the British Society for Rheumatology guidelines to determine response to anti-tumour necrosis factor α (anti-TNFα) treatment.2 A reduction in DAS28 of >1.2 is considered significant improvement, as is a reduction in DAS28 score to <3.2. These figures are important, as under current guidelines clinicians are advised to discontinue anti-TNF treatment if either of these criteria is not achieved at 3 months.
In the course of reviewing decisions on whether or not to continue anti-TNF therapy, we identified several patients in whom the change in DAS28 score did not correlate with clinical findings. It was also noted that the clinicians relied heavily on the change in DAS28 score to determine if the treatment should be continued. In some cases, a relatively insignificant change in erythrocyte sedimentation rate (ESR) seemed to be responsible for a disproportionately great change in the DAS28 score.

To give an example, a 53 year old patient was treated with infliximab. At baseline his patient global assessment was 24, he had 10 swollen and five tender joints, and his ESR was 13 mm/1st h, resulting in a DAS28 score of 5.25. At the 3 month review the patient global assessment was 25; there were eight swollen and two tender joints, and the ESR was 4 mm/h. The second DAS28 score was 3.8, an impressive improvement of 1.45. Thus, even though there had been little change in ESR, there had been a considerable clinical improvement of the patient, where the score seems to conflict with the assessments of the patient and clinician. In these cases misinterpretation may be avoided by careful evaluation of the individual components of the DAS28 score. It may be necessary to modify the guidelines to take into account situations where the change in DAS28 score is not representative of the clinical situation.

REFERENCE


No improvement in a pilot study of tai chi exercise in rheumatoid arthritis

T Uhlig, C Larsson, A-G Hjorth, S Ødegård, T K Kvien

T ai chi, originally a Chinese martial arts, practises physical and mental integration with large, slow, and gracious movements. Tai chi has been shown to improve balance and prevent falls,1 increase flexibility,2 improve physical function,3 and has recently been applied in osteoarthritis.4 Little is known about possible beneficial effects of tai chi in rheumatoid arthritis (RA). We therefore performed an 8 week pilot study to explore the efficacy of a tai chi instruction programme on disease related measures in patients with RA.

PATIENTS AND METHODS

Fifteen women with RA aged 40–70 years (mean (SD) age 57.0 (8.6) years, mean (SD) disease duration 12.3 (5.7) years) were included. Patients were selected from the Oslo RA register and included.

Before, after 4 weeks of intervention, and within 1 week after completion of the 8 week intervention, patients were examined by blinded assessors. Self reported health status included the HAQ, Short Form-36 (SF-36), physical scales from the Arthritis Impact Measurement Scales (AIMS-2), pain, global assessment of disease activity, fatigue (100 mm visual analogue scale), and self efficacy.

At the final examination patients stated preferences for tai chi compared with previous conventional exercise, considering the usefulness of the method and the enjoyment experienced (100 mm Likert scales (50 = equality, 100 favours tai chi)). Physical performance tests measured muscle function in the shoulders and arms (high scores = good function), the index of muscle function in the lower extremities (low scores = good function), grip strength...
patients can adapt to the concept of tai chi and gradually increase exercise intensity. Furthermore, several of the physical performance measures showed a ceiling effect, with good scores at baseline, and measures with higher responsiveness should be selected. Tai chi has in other studies improved arthritic symptoms in osteoarthritis, but not in RA. These findings from a pilot study do not justify a controlled trial, but support further explorative investigations of tai chi in RA.

RESULTS AND DISCUSSION

All 15 patients completed the 8 week intervention and all assessments. No injuries were received during the exercise sessions. Self reported health status measures did not improve or deteriorate during the study (Table 1). Similarly, no changes were seen in the performance measures (muscle strength, flexibility, balance, and cardiovascular fitness), joint counts, laboratory measures for inflammation, and disease activity. Patients, with the exception of two, clearly preferred tai chi to their previous physiotherapeutic intervention, finding it more useful and more enjoyable.

Tai chi instruction and exercise over 8 weeks in this study was safe and feasible, but it did not improve measures of physical function, self reported health status, or disease activity. However, most study subjects clearly favoured tai chi compared with other physical exercise. A major study limitation was the small number of subjects, and another, the short follow up. Usually an intervention period of 10–12 weeks with tai chi has been advocated, so that patients can adapt to the concept of tai chi and gradually increase exercise intensity. Furthermore, several of the physical performance measures showed a ceiling effect, with good scores at baseline, and measures with higher responsiveness should be selected. Tai chi has in other studies improved arthritic symptoms in osteoarthritis, but not in RA.

These findings from a pilot study do not justify a controlled trial, but support further explorative investigations of tai chi in RA.

Table 1 Health status, performance tests, and clinical measures before, during, and after intervention with tai chi exercise

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Baseline</th>
<th>4 Weeks</th>
<th>8 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAQ (0–3)</td>
<td>1.09 (0.83 to 1.35)</td>
<td>0.99 (0.71 to 1.27)</td>
<td>1.07 (0.73 to 1.37)</td>
</tr>
<tr>
<td>Pain (0–100)</td>
<td>32 (19 to 43)</td>
<td>32 (18 to 46)</td>
<td>34 (24 to 45)</td>
</tr>
<tr>
<td>Patient global (0–100)</td>
<td>30 (21 to 40)</td>
<td>35 (21 to 48)</td>
<td>32 (23 to 41)</td>
</tr>
<tr>
<td>Fatigue (0–100)</td>
<td>42 (27 to 57)</td>
<td>39 (24 to 54)</td>
<td>48 (35 to 62)</td>
</tr>
<tr>
<td>SF-36 (0–100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emotional function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role emotional</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS2 (0–10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walking and bending</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hand and finger function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self efficacy (10–100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Function of arm/shoulder (0–60)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index of muscle function total (0–40)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General mobility (0–6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle strength (0–14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance/coordination (0–10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endurance (0–10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grip strength (max dominant hand)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse after 6 minutes walking (/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Minute walking distance (m)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results are shown as mean (95% confidence interval).
Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab

F Broussais, M Kawashima, H Marotte, P Miossec

Cases of lymphoma and tuberculosis (TB) have been described in patients receiving tumour necrosis factor α (TNFα) inhibitors.1 2 We report a case of chronic myeloid leukaemia (CML) and TB, where molecular markers could be followed in a rheumatoid patient treated with infliximab.

CASE REPORT
A 56 year old white woman, with a 2 year history of refractory and destructive rheumatoid arthritis (RA), had been treated with methotrexate (MTX, 10 mg/week). As this was not effective, MTX was increased to 15 mg/week, and she received a total amount of about 1250 mg. Because of persistent active disease and high erythrocyte sedimentation rate (44 mm/1st h) with high platelet count at 0.6 x 1012/l, infliximab was combined with MTX (15 mg/week) in August 2001 at 3 mg/kg every 8 weeks.3 It should be noted that at that time TB prophylaxis before starting anti-TNFα treatment was not yet organised as it is today.

Although the disease improved, thrombocytosis, first considered as possibly related to inflammation, increased up to 1.1 x 1012/l in January 2002. Bone marrow aspiration demonstrated typical features of CML with the (9;22) (q34;q11) translocation. Infliximab was stopped. After a month of treatment with hydroxycarbamide (500 mg, three times a day), the platelet count decreased to 0.5 x 1012/l. Hydroxycarbamide was stopped and interferon alfa (IFNα) treatment was replaced by STI 571 at 600 mg/day. At this level of 0.5 x 1012/l, this level decreased with myelosuppressive agents to 0.5 x 1011/l. In addition, using RNA collected from this patient before infliximab treatment, the transcript could be detected at 0.5 x 1012/l before the first infusion, indicating that CML was present before infliximab treatment. Its rate of expression appeared to increase during infliximab treatment, suggesting that such treatment has an effect on clonal expansion, although the mutation was already detected before treatment was started (fig 1).

To our knowledge, this is the first description of a diagnosis of CML during infliximab treatment.7 Available data are insufficient to draw conclusions as to whether CML developed as part of the natural history of the underlying medical conditions, or whether it occurred as a complication related to a cell mediated immune defect.3

Bcr-abl transcript was detected by reverse transcriptase-polymerase chain reaction at the time of CML diagnosis at a level of 0.5 x 10−2. This level decreased with myelosuppressive agents to 0.5 x 10−4. In addition, using RNA collected from this patient before infliximab treatment, the transcript could be detected at 0.5 x 10−3 before the first infusion, indicating that CML was present before infliximab treatment. Its rate of expression appeared to increase during infliximab treatment, suggesting that such treatment has an effect on clonal expansion, although the mutation was already detected before treatment was started (fig 1).
The simultaneous occurrence of TB suggests that this patient had a cell mediated immune defect because she developed TB quickly after the initiation of infliximab treatment as for the other anti-TNF related cases. To explore the systemic immune function, a bioassay based on the induction of IFN\(\gamma\) production by interleukin (IL) 12 and/or IL18 used peripheral blood mononuclear cells (PBMC) from this patient, 15 patients with RA, and 14 healthy controls. PBMC from this patient were collected during treatment for RA.

Th1 immune defect in this and other patients with RA. PBMC from the patient, control patients with RA (n = 15), and healthy controls (n = 14) were stimulated with or without 1 ng/ml of IL12 or a combination of IL12 (1 ng/ml) and IL18 (5 ng/ml). IFN\(\gamma\) concentrations in the culture supernatants were measured by an enzyme linked immunosorbent assay (ELISA). p Values compare controls and patients with RA.

**DISCUSSION**

Screening for TB, as would be done today in this particular case, should have prevented the severe reactivation seen here. Although such a procedure has been particularly effective, the long term immunosuppressive effects of infliximab are unknown. Infliximab treatment is still too recent for a full assessment of its long term safety to be made, and post-marketing follow up is required to define its long term effect on malignancies, particularly on lymphomas and leukemias.

**Authors’ affiliations**

F Brousais, M Kawashima, H Marotte, P Miossec, Departments of Immunology and Rheumatology and HCL-bioMérieux Research Unit on Rheumatoid Arthritis, Lyon, France

Correspondence to: Professor P Miossec, Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France; miossec@univ-lyon1.fr

Accepted 20 June 2004

**REFERENCES**


---

**Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren’s syndrome**

Y Naito, I Matsumoto, E Wakamatsu, D Goto, T Sugiyama, R Matsumura, S Ito, A Tsutsumi, T Sumida

Sjögren’s syndrome (SS) is an autoimmune disease characterised by lymphocytic infiltration into the lachrymal and salivary glands, leading to dry eyes and mouth. Infiltration is also found in the kidneys, lungs, thyroid, and liver. Immunohistochemical studies have shown that most infiltrating lymphocytes around the labial salivary and lachrymal glands, and kidneys are CD4 positive T cells. Previous studies with polymerase chain reaction provide evidence about the T cell receptor Vβ and Vγ genes on these T cells, and sequence analysis of the CDR3 region indicates some conserved amino acid motifs, supporting the notion that infiltrating T cells recognise relatively few epitopes on autoantigens.

Candidate autoantigens recognised by T cells infiltrating the labial salivary glands of patients with SS have been analysed, and Ro/SSA 52 kDa, α-amylase, heat shock protein, and T cell receptor BV69 have been identified. However, there is no direct evidence that these reactive T cells really attack and destroy the salivary glands. In contrast, the presence of autoantibodies (Abs) against M3 muscarinic acetylcholine receptor (M3R) has been reported, and it is suggested that an immune reaction to M3R plays a crucial part in the generation of SS. Robinson, et al demonstrated that human anti-M3R Abs reduce the secretory function in NOD.Ignnull mice. Moreover, Bacman et al clearly showed that human Abs against the second extracellular loop of M3R could...
Letters

patients with SS. To test this production of saliva and tears after stimulation of acetylcholine, and thus they should be key receptors involved in the activation of nitric oxide synthase coupled to the lachrymal gland M3R, suggesting that anti-M3R Abs are a new marker of dry eye SS. The M3Rs are expressed on salivary and lachrymal glands, and thus they should be key receptors involved in the production of saliva and tears after stimulation of acetylcholine. Hence, autoantibodies against M3R could interfere with the production of saliva and tears. To test this hypothesis we analysed the prevalence of anti-M3R Abs in patients with SS.

Approval for this study was obtained from the local ethics committee and written informed consent was obtained from all patients and volunteers who participated in this study.

METHODS

Serum samples were collected from 122 Japanese patients with primary SS and 102 Japanese patients with secondary SS followed up at the Department of Internal Medicine, University of Tsukuba Hospital, Japanese Red Cross Mito Hospital, and Shimosizu National Hospital. All patients with SS satisfied the Japanese Ministry of Health criteria for the classification of SS. We also recruited 105 patients with rheumatoid arthritis, 97 with systemic lupus erythematosus, and 128 healthy subjects from our University.

A 25mer peptide (KRTVPPGECFIQELSEPITFTGTAI) corresponding to the sequence of the second extracellular loop of the human M3R was synthesised (Kurabo Industries). Peptide solution (final concentration 1 mg/ml) was added as alkaline phosphatase substrate. Plates were incubated for 1 hour at room temperature and the optical density at 405 nm was measured by plate spectrophotometry (Bio-Rad Laboratories, Hercules, CA; fig 1). Determinations were performed in triplicate and standardised between experiments.

RESULTS AND DISCUSSION

The 25mer synthetic amino acid encoding the second extracellular domain of M3R was used as the antigen, because this portion has an important role in intracellular signalling. The binding activity of Abs to the second extracellular domain of M3R is dependent on the concentration of Abs using serial-diluted quantitative assay (data not shown). Figure 1 shows that Abs against M3R were more commonly detected in the serum of patients with primary SS (11/122 (9%), p<0.05) and secondary SS (14/102 (14%), p<0.05) than in those with other autoimmune diseases such as rheumatoid arthritis (1/105 (1%)) and systemic lupus erythematosus (0/97 (0%)), or healthy subjects (3/128 (2%)). These results clearly showed that autoantibodies against M3R are specifically present in SS, suggesting that anti-M3R Abs could be used as a diagnostic marker in a subgroup of patients with SS (9–14%). The proportions of patients positive for anti-M3R Ab and anti-SSA Ab, anti-SSB Ab, rheumatoid factor, and antinuclear factor were 68%, 29%, 57%, and 83%, respectively. Thus, anti-SSB Ab is strongly associated with anti-M3R Ab (p<0.05), although the homology between SSB and the M3R molecule is very low and the detailed mechanism remain unclear. The clinical feature is not significantly different between in patients with SS positive for anti-M3R Ab and negative patients.

In conclusion, we detected autoantibodies against M3R in a subgroup of patients with SS, suggesting that anti-M3R Ab could be used as a new diagnostic marker for SS. Further experiments on the functional analysis of anti-M3R Abs in SS using M3R transfectant cell lines should shed light on the relationship between the presence of anti-M3R autoantibodies and the pathogenesis of SS.

Authors’ affiliations

Y Naito, I Matsumoto, E Wakamatsu, D Goto, S Ito, A Tsutsumi, T Sumida, University of Tsukuba, Ibaraki, Japan

T Sugiyama, Shimosizu National Hospital, Chiba, Japan

R Matsumura, Toho University Sakurahospital, Chiba, Japan

Correspondence to: Professor T Sumida, Department of Internal Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City, Ibaraki 305-8575, Japan; tsumida@md.tsukuba.ac.jp

Accepted 17 July 2004

REFERENCES


www.annrheumdis.com